Company

Our Mission

To provide quick and accurate flow cytometry results in a compact and easy-to-use platform designed for use on the manufacturing floor and at point-of-care.

The Accellix platform enable its partners in the field of cell therapy to meet their critical quality control requirements as they advance life-changing therapies benefiting patients worldwide.

The Accellix team is an interdisciplinary group with deep experience in all aspects of the platform. Accellix has growing offices in Jerusalem and San Jose, CA.

Accelix Customized Cartridge Example

Executive Team

  • Nir Nimrodi

    Nir Nimrodi
    Chairman and Chief Executive Officer

    Nir joined Accellix as its Executive Chairman on June 2019. On January 2020, Nir was appointed as the company’s Chairman and Chief Executive Officer. Nir brings 25 years of diverse international experience in both start-ups and large global businesses in the life science, pharmaceutical, and biotechnology industries. Prior to joining Accellix, Nir served as the Chief Business Officer of Intrexon Corporation, a leader in synthetic biology. Intrexon and its partners were among the pioneering companies in the field of immuno-oncology as well as several other gene therapy programs.

    Prior to Intrexon, Nir held several executive roles at Life Technologies (now part of Thermo Fisher). While at Life, Nir served as Chief Executive Officer and Board Member of Life Technologies Israel, Head of Protein Technologies, as well as Vice President and General Manager of Food Safety and Animal Health. Prior to his seven years at Life Technologies, he was the CEO of Proneuron Biotechnologies and Mindsense Biosystems. Earlier in his career, Nir was a Director of Finance for Teva Pharmaceuticals.

    Nir received his BA in Economics and his MBA from the Tel Aviv University.

  • Rey Mali

    Rey Mali
    VP Sales & Marketing

    Rey joined Accellix as its Vice President Sales and Marketing on July 2019. She has served as a Product Development and Marketing leader for the prior 14 years in both hi-tech and biotech companies.

    Rey has a graduate degree in Medical Research and a MBA from The University of California, Berkeley and started her career in pharmaceutical sales at Merck Pharmaceuticals. She then joined a biotech startup that was acquired by Life Technologies (Thermo Fisher) as a Field Applications Scientist (FAS) increasing customer acquisition and retention and later was promoted to a Global Product Manager role at Life Technologies, where she launched and managed products in the molecular biology space. She then transitioned to a Sr. Product Marketing Manager at Illumina, where she launched and managed products in the sequencing space, and later served as the Product Marketing Director at Twist Bioscience leading the global marketing team towards commercial product launches and a successful IPO. Recently, she has been working at the Chan Zuckerberg Initiative (CZI) leading the Product Marketing efforts of free technological tools to advance medical research.

  • Reed Hickey

    Reed Hickey
    VP Operations

    Reed joined Accellix as its Vice President Operations on September of 2019. He brings more than 25 years of diverse experience in the life science industry, and particularly the tools industry. Reed has extensive operational experience as well as commercial operations experience.

    Early in his career, Reed gained 15 years of academic research experience in the molecular biology and developmental cardiology fields. He started at the University of California San Diego, as a research associate and later became a laboratory manager at Yale University.

    Reed joined Invitrogen in 2005, where he supported the creation of a protein expression custom business. In 2007, he transitioned to the management side of the business and has held various roles culminating in leading the synthetic biology and sample preparation business units at Thermo Fisher. As part of his business leadership role, Reed managed nine global sites for the custom oligo business and has built of the GeneArt gene synthesis site in Pleasanton, California. In 2017 Reed took over leading product management for Twist Bioscience. During his time at Twist, Reed was pivotal in the scaling up of the business, leading to the IPO of the company in 2018.

  • Zion Botesazan

    Zion Botesazan
    VP Hardware & Software

    Zion joined Accellix in 2013. He has served in key roles since and is currently Vice President of Hardware and Software. He brings to the company more than 20 years of diverse experience in the medical device industry.

Board of Directors

  • Nir Nimrodi

    Nir Nimrodi
    Accellix, Intrexon, Life Technologies, Proneuron, Teva

    Nir joined Accellix as its Executive Chairman on June 2019. On January 2020, Nir was appointed as the company’s Chairman and Chief Executive Officer. Nir brings 25 years of diverse international experience in both start-ups and large global businesses in the life science, pharmaceutical, and biotechnology industries. Prior to joining Accellix, Nir served as the Chief Business Officer of Intrexon Corporation, a leader in synthetic biology. Intrexon and its partners were among the pioneering companies in the field of immuno-oncology as well as several other gene therapy programs.

    Prior to Intrexon, Nir held several executive roles at Life Technologies (now part of Thermo Fisher). While at Life, Nir served as Chief Executive Officer and Board Member of Life Technologies Israel, Head of Protein Technologies, as well as Vice President and General Manager of Food Safety and Animal Health. Prior to his seven years at Life Technologies, he was the CEO of Proneuron Biotechnologies and Mindsense Biosystems. Earlier in his career, Nir was a Director of Finance for Teva Pharmaceuticals.

    Nir received his BA in Economics and his MBA from the Tel Aviv University.

  • Mark Chess

    Mark Chess
    Infinity

    Mark joined Accellix’s board in 2014 and served as its previous Executive Chairman. He is a Founder and Partner at FinTLV and Chairman of Kaiima Bio-Agritech.

    Mark was a managing director at Infinity Equity, an $800M private equity fund. He was at Infinity for 17 years and helped establish the FBR Infinity II Fund in 2001 and the world’s first foreign currency fund in China in 2005 (Infinity-CSVC).

    Mark graduated with a degree in Business Honors from the McCombs School of Business at the University of Texas at Austin.

  • Steven L. Hurwitz

    Steven L. Hurwitz
    Trisun Financial Group

    Steven L. Hurwitz joined the Accellix board in June 2020. Since 1989, Mr. Hurwitz has been President and Co-Founder of Trisun Financial Group, LLC — an equity financing and real estate development company based in Baltimore, Maryland. Mr. Hurwitz is also Founder and President of Trisib Capital Partners, LLC. (TCP), which serves as his private family office. TCP manages venture capital funds, focusing on early- and growth-stage equity investments primarily focused in information technology and life science companies.

  • Charles (Chuck) Piazza

    Charles (Chuck) Piazza
    Life Technologies, Cambrex, FMC

    Chuck joined Accellix’s board on August 2019. He has over 35 years of global experience within the life science industry serving the pharmaceutical, biotechnology, and medical research sectors. His recent positions included Vice President and General Manager for the Molecular Biology Research products division of Life Technologies (now part of Thermo Fisher) and Vice President for Global Sales Operations and Pricing.

    Prior to joining Life Technologies (ThermoFisher), Chuck was Vice President and General Manager for molecular biology tools at Cambrex BioSciences (now part of Lonza), a supplier of molecular biology and cell culture products, including normal human and hematopoietic stem cells. Earlier in his career, he also served as the Director of Sales and Marketing at FMC BioProducts, a life science reagents division of FMC Corporation.

  • Michaël Reynier

    Michaël Reynier
    bioMérieux

    Michaël joined Accellix’s board in June 2020 as part of the bioMérieux investment in Accellix. Michaël is Vice President of the Healthcare Business within the Industrial Microbiology Unit of bioMérieux. Michaël leads a team dedicated to developing and providing best in class Quality Control solutions for the Pharma Industry.
    Michaël joined bioMérieux in 2011 as Special Adviser to the President and CEO and secretary of the Executive Committee. He then joined the Industrial Microbiology Unit, where he was in charge of Strategy, Innovation and Portfolio Management. Michaël was appointed as VP of the Healthcare Business in 2015. Prior to joining bioMérieux, Michael held various responsibilities within the French public administration, in the field of economic development and competitiveness.

  • Bruce Sholk

    Bruce Sholk
    Axcel Partners

    Bruce joined Accellix’s board in 2011 and currently serves as the lead outside director. He is the Managing Partner of Axcel Partners, a private equity investment partnership. Bruce has spent the last 35 years actively involved in guiding and financing companies from start-up through commercial success. His involvement with Accellix began shortly after the Company was founded, and along with his investment partners has provided significant support to the company since 2012.

    Bruce received his BA from the University of Florida and MBA from Carnegie-Mellon University. In addition to his investment activities, he holds a range of board leadership positions in non-profit organizations on a local, national and international basis.

  • Barry L. Zubrow

    Barry L. Zubrow
    J.P. Morgan, Goldman Sachs

    Barry joined Accellix’s board on August 2019. He is President of ITB llc, a family office investment management company. Barry serves in various board capacities, including on the boards of the Canadian Imperial Bank of Commerce (CIBC), CIBC Bancorp USA, and the Advisory Board of The Promontory Financial Group (an IBM Company), as well as a Lecturer in Law at the University of Chicago Law School.

    Over a 40-plus year career in finance, Barry served in various senior management executive positions at JPMorgan Chase & Co and Goldman Sachs Group. He has also served as an advisor to New Jersey Governors Corzine and Murphy. He has had numerous board leadership positions on non-profit boards, including Juvenile Law Center, Berklee College of Music, and Haverford College.

    Barry received his BA from Haverford College in 1975, an MBA in 1979 from the University of Chicago Graduate School of Business, and his JD in 1980 from the University of Chicago Law School.